Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024

IF 4.3 4区医学 Q1 INFECTIOUS DISEASES Influenza and Other Respiratory Viruses Pub Date : 2025-03-09 DOI:10.1111/irv.70081

Liliana Antunes, Madelyn Rojas-Castro, Marcos Lozano, Iván Martínez-Baz, Isabel Leroux-Roels, Maria-Louise Borg, Beatrix Oroszi, Margaret Fitzgerald, Ralf Dürrwald, Ligita Jancoriene, Ausenda Machado, Goranka Petrović, Mihaela Lazar, Lenka Součková, Sabrina Bacci, Jennifer Howard, Nuno Verdasca, Luca Basile, Jesús Castilla, Silke Ternest, Aušra Džiugytė, Gergő Túri, Roisin Duffy, Carolin Hackmann, Monika Kuliese, Verónica Gomez, Zvjezdana Lovrić Makarić, Alexandru Marin, Petr Husa, Nathalie Nicolay, Angela M. C. Rose, VEBIS SARI VE network team

{"title":"Effectiveness of the XBB.1.5 COVID-19 Vaccines Against SARS-CoV-2 Hospitalisation Among Adults Aged ≥ 65 Years During the BA.2.86/JN.1 Predominant Period, VEBIS Hospital Study, Europe, November 2023 to May 2024","authors":"Liliana Antunes, Madelyn Rojas-Castro, Marcos Lozano, Iván Martínez-Baz, Isabel Leroux-Roels, Maria-Louise Borg, Beatrix Oroszi, Margaret Fitzgerald, Ralf Dürrwald, Ligita Jancoriene, Ausenda Machado, Goranka Petrović, Mihaela Lazar, Lenka Součková, Sabrina Bacci, Jennifer Howard, Nuno Verdasca, Luca Basile, Jesús Castilla, Silke Ternest, Aušra Džiugytė, Gergő Túri, Roisin Duffy, Carolin Hackmann, Monika Kuliese, Verónica Gomez, Zvjezdana Lovrić Makarić, Alexandru Marin, Petr Husa, Nathalie Nicolay, Angela M. C. Rose, VEBIS SARI VE network team","doi":"10.1111/irv.70081","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case–control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14–59 days and 34% at 60–119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.</p>\n </div>","PeriodicalId":13544,"journal":{"name":"Influenza and Other Respiratory Viruses","volume":"19 3","pages":""},"PeriodicalIF":4.3000,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Influenza and Other Respiratory Viruses","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/irv.70081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

We estimated the effectiveness of the adapted monovalent XBB.1.5 COVID-19 vaccines against PCR-confirmed SARS-CoV-2 hospitalisation during the BA.2.86/JN.1 lineage-predominant period using a multicentre test-negative case–control study in Europe. We included older adults (≥ 65 years) hospitalised with severe acute respiratory infection from November 2023 to May 2024. Vaccine effectiveness was 46% at 14–59 days and 34% at 60–119 days, with no effect thereafter. The XBB.1.5 COVID-19 vaccines conferred protection against BA.2.86 lineage hospitalisation in the first 4 months post-vaccination.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

求助全文

约1分钟内获得全文去求助

来源期刊

Influenza and Other Respiratory Viruses 医学-病毒学

CiteScore

7.20

自引率

4.50%

发文量

120

审稿时长

6-12 weeks

期刊介绍： Influenza and Other Respiratory Viruses is the official journal of the International Society of Influenza and Other Respiratory Virus Diseases - an independent scientific professional society - dedicated to promoting the prevention, detection, treatment, and control of influenza and other respiratory virus diseases. Influenza and Other Respiratory Viruses is an Open Access journal. Copyright on any research article published by Influenza and Other Respiratory Viruses is retained by the author(s). Authors grant Wiley a license to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified.